Wall Street analysts expect Aevi Genomic Medicine Inc (NASDAQ:GNMX) to announce earnings per share (EPS) of ($0.16) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Aevi Genomic Medicine’s earnings. The lowest EPS estimate is ($0.17) and the highest is ($0.15). Aevi Genomic Medicine posted earnings of ($0.23) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 30.4%. The firm is expected to issue its next quarterly earnings results on Thursday, November 1st.
According to Zacks, analysts expect that Aevi Genomic Medicine will report full-year earnings of ($0.60) per share for the current financial year, with EPS estimates ranging from ($0.61) to ($0.59). For the next financial year, analysts anticipate that the firm will report earnings of ($0.92) per share, with EPS estimates ranging from ($1.27) to ($0.57). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Aevi Genomic Medicine.
Aevi Genomic Medicine (NASDAQ:GNMX) last announced its quarterly earnings results on Thursday, August 2nd. The biotechnology company reported ($0.14) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.01.
Separately, ValuEngine raised shares of Aevi Genomic Medicine from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 2nd.
A number of large investors have recently made changes to their positions in the business. Wedbush Securities Inc. bought a new position in Aevi Genomic Medicine in the 2nd quarter valued at $233,000. JPMorgan Chase & Co. lifted its holdings in shares of Aevi Genomic Medicine by 4,715.1% during the 1st quarter. JPMorgan Chase & Co. now owns 101,118 shares of the biotechnology company’s stock worth $203,000 after acquiring an additional 99,018 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of Aevi Genomic Medicine by 515.8% during the 4th quarter. Renaissance Technologies LLC now owns 93,600 shares of the biotechnology company’s stock worth $112,000 after acquiring an additional 78,400 shares during the last quarter. 22.80% of the stock is owned by hedge funds and other institutional investors.
Aevi Genomic Medicine traded down $0.03, hitting $0.98, during trading hours on Tuesday, MarketBeat reports. The stock had a trading volume of 17,467 shares, compared to its average volume of 106,832. Aevi Genomic Medicine has a one year low of $0.83 and a one year high of $2.65.
About Aevi Genomic Medicine
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease.
Further Reading: Price to Earnings Ratio (PE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with MarketBeat.com's FREE daily email newsletter.